Novel 3'-spiro nucleoside analogues of the potent human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitor TSAO-T have been designed, synthesized and tested for their in vitro anti-retroviral activity against HIV-1. In these TSAO analogues the spiro amino-oxathioledioxide moiety was replaced by other spiro moieties that maintained an NH group at the same position as the 4″-NH2 group in the prototype compound TSAO-T. Anti-HIV-1 activity, although around 100-fold less pronounced than that of the parent TSAO-m3T derivative, was observed for the spiro oxazolone derivative. The spiro oxathiazoledioxide compound also showed antiviral activity. The corresponding β-D-xylofuranosyl analogues were devoid of antiviral activity; this is in accordance with the behaviour of TSAO-m3T. None of the test compounds were inhibitory to HIV-2 replication. The markedly decreased potency of the spiro oxathiazoledioxide and oxazolone compounds against HIV-1 replication is in agreement with their decreased anti-HIV-1 RT activity.
AlvarezR., VelázquezS., San-FélixA., AquaroS., De ClercqE., PernoC-F, KarlssonA., BalzariniJ., & CamarasaM.J. (1994) 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl-β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxidc) (TSAO) analogues. Synthesis and anti-HIV-1 activity. Journal of Medicinal Chemistry37: 4185-4194.
2.
BalzariniJ., Pérez-PérezM.J., San-FélixA., ScholsD., PernoC.F., VandammeA.M., CamarasaM.J., & De ClercqE. (1992a) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathi-ole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA89: 4392-4396.
3.
BalzariniJ., Pérez-PérezM.J., San-FélixA., VelázquezS., CamarasaM.J., & De ClercqE., (1992b) [2′,5′-bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy36: 1073-1080.
4.
BalzariniJ., Pérez-PérezM.J., San-FélixA., CamarasaM.J., BathurstI.C., BarrP.J., & De ClercqE. (1992c) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue 2′,5′-bis-O-(t-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) thymine (TSAO-T). Journal of Biological Chemistry267: 11831-11838.
5.
BalzariniJ., CamarasaM.J., & KarlssonA. (1993a) TSAO derivatives: highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs of the Future18: 1043-1055.
6.
BalzariniJ., KarlssonA., VandammeA.M., Pérez-PérezM.J., ZhangH., VrangL., ÖbergB., BäckbroK., UngeT., San-FélixA., VelázquezS., CamarasaM.J., & De ClercqE. (1993b) Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the novel class of HIV-1-specific TSAO nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors. Proceedings of the National Academy of Sciences, USA90: 6952-6956.
7.
BalzariniJ., VelázquezS., KarlssonA., Pérez-PérezM.J., San-FélixA., CamarasaM.J., & De ClercqE. (1993c) Human immunodeficiency virus type 1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl-β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1 non-nucleoside analogues. Molecular Pharmacology43: 109-114.
8.
BalzariniJ., KleimJ.P., RiessG., CamarasaM.J., De ClercqE., & KarlssonA. (1994) Sensitivity of (138 GLU→LYS) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochemical and Biophysical Research Communications201: 1305-1312.
9.
BaxA., & SummersM.F. (1986) 1H and 13C assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum NMR. Journal of the American Chemical Society108: 2093-2094.
10.
BoyerP.L., DingJ., ArnoldE., & HughesS.H. (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy38: 1909-1914.
11.
Calvo-MateoA., CamarasaM.J., Díaz-OrtizA., & de las HerasF.G. (1988a) Novel aldol-type cyclocondensation of O-mesyl-(methylsulphonyl)-cyanohydrins. Application to the stereospecific synthesis of branched-chain sugars. Journal of the Chemical Society Chemical Communications1114-1115.
12.
Calvo-MateoA., CamarasaM.J., Díaz-OrtizA., de las HerasF.G., & AlemanyA. (1988b) Synthesis of 3′-C-cyano-3′-deoxypentofuranosylthymine nucleosides. Tetrahedron44: 4895-4903.
13.
CamarasaM.J., Pérez-PérezM.J., San-FélixA., BalzariniJ., & De ClercqE. (1992) 3′-Spironucleosides (TSAO derivatives), a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″,2″-dioxide] pyrimidine nucleosides. Journal of Med-icinal Chemistry35: 2721-2727.
14.
CamarasaM.J., Pérez-PérezM.J., VelázquezS., San-FélixA., AlvarezA., IngateS., JimenoM.L., KarlssonA., De ClercqE., & BalzariniJ. (1995) TSAO derivatives: highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides and Nucleotides14: 585-594.
15.
CushleyR.J., WatanabeK.A., & FoxJ.J. (1967) Nucleosides. XXXVIII. Proton magnetic resonance studies of acetylated nucleosides. Journal of the American Chemical Society89: 394-400.
16.
GarcíaM.V., MenéndezJ.C., VillacampaM., & SöllhuberM.M. (1991) Study of the reaction between cyanohydrins and chlorosulfonyl isocyanate. A new, efficient method for the one-pot synthesis of 2,4-oxazolidinediones. Synthesis697-698.
17.
GravesK.L., ButlerM.M., & HardyL.W. (1992) Roles of Cys148 and Asp179 in catalysis by deoxycytidilate from bacteriophage T4 examined by site-directed mutagenesis. Biochemistry31: 10315-10321.
18.
HansskeF., MadejD., & RobinsM.J. (1984) 2′- and 3′-ketonucleosides and their arabino and xylo reduction products. Tetrahedron40: 125-135.
19.
HardyL.W., & NalivaikaE. (1992) Asn177 in Escherichia coli thymidylate synthase is a major determinant of pyrimidine specificity. Proceedings of the National Academy of Sciences, USA89: 9725-9229.
20.
HayakawaH., TanakaH., ItohN., NakajiwaM., MiyasakaT., YamaguchiK., & IitakaY. (1987) Reaction of organometallic reagents with 2′- and 3′-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2′- and 3′-positions. Chemical and Pharmaceutical Bulletin35: 2605-2608.
21.
IngateS., Pérez-PérezM.J., De ClercqE., BalzariniJ., & CamarasaM.J. (1995) Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′- positions of the sugar moiety. Antiviral Research27: 281-299.
22.
JonckheereH., TaymansJ.M., BalzariniJ., VelázquezS., CamarasaM.J., DesmyterJ., De ClercqE., & AnnéJ. (1994) Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsUyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2′,2′-dioxide)](TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunitJournal of Biological Chemistry269: 25255-25258.
23.
MyersG., KorberB., Wain-HobsonS., TehjeangK., HendersonL., & Paolakis (Editors) (1994) Human Retroviruses and AIDS-1994.Los Alamos: Los Alamos National Laboratory.
24.
Pérez-PérezM.J., CamarasaM.J., Díaz-OrtizA., San-FélixA., & de las HerasF.G. (1991) Stereospecific synthesis of branched-chain sugars by a novel aldol-type cyclocondensation. Carbohydrate Research216: 399-411.
25.
Pérez-PérezM.J., San-FélixA., BalzariniJ., De ClercqE., & CamarasaM.J. (1992) TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl-β-D-ribofuranosyl]-3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″,2″-diox ide]pyrimidine and pyrimidine modified nucleosides. Journal of Medicinal Chemistry35: 2988-2995.
26.
Pérez-PérezM.J., BalzariniJ., De ClercqE., & CamarasaM.J. (1993) Glycosyl-oxycarbonylaminosulfonyl-2′,3′-dideoxynucleoside derivatives as lipophilic nucleotide mimics, synthesis and anti-HIV activity. Bioorganic and Medicinal Chemistry Letters1: 279-284.
27.
San-FélixA., VelázquezS., Pérez-PérezM.J., BalzariniJ., De ClercqE., CamarasaM.J. (1994) Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-,5- and 6-substituted pyrimidine analogues. Journal of Medicinal Chemistry37: 453-460.
28.
SargesR., HowardH.R., & KelbaughP.R. (1982) Synthesis of optically active spirohydantoins by asymmetric induction. Hydantoin formation from amino nitriles and chlorosulfonyl isocyanate. Journal of Organic Chemistry47: 4081-4084.
29.
SummersM.F., MarzilliL.G., & BaxA. (1986) Complete 1H and 13C assignments of coenzyme B12 through the use of new two-dimensional NMR experiments. Journal of the American Chemical Society108: 4285-4294.
30.
VelázquezS., San-FélixA., Pérez-PérezM.J., BalzariniJ., De ClercqE., & CamarasaM.J. (1993) TSAO analogues. 3. Synthesis and anti-HIV-1 activity of [2′,5′-bis-O-(tert-butyldimethylsilyl-β-D-ribofuranosyl]-3′spiro-5′-[4′-amino-1″,2″-oxathiole-2″,2″-dioxide] purine and purine-modified nucleosides. Journal of Medicinal Chemistry36: 3230-3239.
31.
VelázquezS., JimenoM.L., CamarasaM.J., & BalzariniJ. (1994) Synthesis of [1-[3′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-arabino- and β-D-ribofuranosyl]cytosine]-2′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)Tetrahedron50:11013-11022.
32.
WitanowskyM., StefaniakL., & WebbG.A. (1993) Annual reports on NMR spectroscopy, vol. 25. Edited by WebbGA. London: Academic Press.
